435 related articles for article (PubMed ID: 30207671)
1. Disease-modifying treatment of amyotrophic lateral sclerosis.
Schultz J
Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
[TBL] [Abstract][Full Text] [Related]
2. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
3. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
4. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
5. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
[TBL] [Abstract][Full Text] [Related]
6. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Dash RP; Babu RJ; Srinivas NR
Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
[TBL] [Abstract][Full Text] [Related]
7. [Drugs for Amyotrophic Lateral Sclerosis].
Ogino M
Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
Noto Y; Shibuya K; Vucic S; Kiernan MC
Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
[TBL] [Abstract][Full Text] [Related]
10. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
Cheah BC; Vucic S; Krishnan AV; Kiernan MC
Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
[TBL] [Abstract][Full Text] [Related]
11. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
[TBL] [Abstract][Full Text] [Related]
13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
14. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
[TBL] [Abstract][Full Text] [Related]
15. Edaravone May Prevent Ferroptosis in ALS.
Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic Lateral Sclerosis: An Update for 2018.
Oskarsson B; Gendron TF; Staff NP
Mayo Clin Proc; 2018 Nov; 93(11):1617-1628. PubMed ID: 30401437
[TBL] [Abstract][Full Text] [Related]
17. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
[TBL] [Abstract][Full Text] [Related]
18. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
19. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
Singh P; Belliveau P; Towle J; Neculau AE; Dima L
Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
[TBL] [Abstract][Full Text] [Related]
20. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
Park JM; Kim SY; Park D; Park JS
Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
